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Early full-term pregnancy is thought to be one of the most effective means of decreasing lifetime breast cancer risk. Paradoxically, 
young women diagnosed with breast cancer shortly after giving birth have a higher risk of dying from their disease. These 
seemingly opposing effects have been largely attributed to mammary epithelial stem cell differentiation and precancerous cell 
proliferation, respectively, induced by pregnancy-associated hormonal changes. However, recent studies suggest that remod-
eling of the cellular microenvironment and extracellular matrix during pregnancy and involution may contribute to the enhanced 
invasive and metastatic potential of breast carcinomas and thus lead to their worse clinical outcome.Breast cancer is one of the most com-
monly diagnosed neoplasms and a lead-
ing cause of cancer associated-death in 
women worldwide. Besides family history, 
lifetime cumulative exposure to reproduc-
tive hormones is the most significant and 
well-characterized risk factor for breast 
cancer. Conversely, early full-term preg-
nancy and multiparity decrease lifetime 
breast cancer risk in women of all ethnic 
groups with the exception of mutation 
carriers of high-penetrance breast can-
cer susceptibility genes (Cullinane et al., 
2005). Supporting this observation, ani-
mal studies demonstrate that pregnancy 
or short-term treatment of virgin rats with 
pregnancy-associated hormones pro-
tects against chemically induced mam-
mary carcinogenesis (Russo et al., 2005a, 
2005b). One potential mechanism for this 
protective effect is that the terminal differ-
entiation of mammary stem cells follow-
ing pregnancy decreases the number of 
cells that could be targeted by oncogenic 
events. In addition, recent comprehen-
sive genomic studies of isolated mam-
mary epithelial cells have demonstrated 
permanent alterations in gene expression 
patterns induced by pregnancy (Russo et 
al., 2005a).
Based on molecular profiling studies, 
it is generally accepted that breast can-
cer is not a single disease with a single 
tumorigenesis pathway, but rather a het-
erogeneous group of diseases with each 
subtype having its own stable phenotype 
maintained during tumor progression. The 
most important determinants of these 
subtypes found to date are the presence 
or absence of estrogen receptor (ER) and 
progesterone receptor (PR), the amplifi-
cation and overexpression of the HER2 
oncogene, and histologic grade. Based on 
these features, breast tumors are divided 
into luminal A, B, and C, HER2+, and 
basal subtypes, and this classification cor-
relates with clinical outcome. It is hypoth-
esized that tumor subtypes reflect the cell 
of origin of the tumor with ER-negative and 
-positive tumors initiating from the earliest 
progenitors and more committed transit-cancer cell march 2006 amplifying cells, respectively. Correlating 
with the proposed existence of subtype-
specific tumor progression pathways, it is 
increasingly evident that risk factors are 
also different for each tumor type. The pro-
tective effect of full-term pregnancy at an 
early age is only observed for ER+/PR+ 
tumors, while folate intake and alcohol 
consumption only influence the risk of ER-negative tumors (Colditz et al., 2004; 
Ursin et al., 2005).
In contrast to its long-term protective 
effect, in young women (under age 35 or 
45 depending on the study) pregnancy 
is associated with a transient increase 
in breast cancer risk (Albrektsen et al., 
2006). Furthermore, breast cancer diag-
nosed shortly (within 2 or 5 years depend-Figure 1. hypothetical model depicting the potential contribution of pregnancy-induced chang-
es in the cellular microenvironment to breast tumor progression
During pregnancy, the number of mammary epithelial cells is dramatically increased, potentially 
at least in part due to the expansion of the stem and/or transit-amplifying cell population. This 
dramatic epithelial cell proliferation is accompanied by an increase in angiogenesis and the 
number of stromal fibroblasts, as well as changes in Ecm. Pregnancy and involution may also 
alter the stem cell niche and basement membrane (Bm). Following lactation and involution, 
the number of mammary epithelial cells, including stem cells, is decreased, together with breast 
density due to degradation of Ecm components. If pregnancy occurs in a woman whose breast 
already contains an “initiated” stem cell that has acquired a tumor-initiating genetic alteration 
(*), or such an initiating event occurs during pregnancy, then the number of these cells can also 
increase, allowing for the acquisition of additional genetic alterations and clonal selection due 
to expanded population size. Increased proteolysis leading to Ecm degradation and potential 
focal disruption of the Bm during involution could promote the further progression of these early-
stage tumors, resulting in invasion and metastatic spreading.151
	 p r e v i e w sing on the study) after a woman gives birth 
has a worse clinical outcome than tumors 
not associated with a recent pregnancy, 
even after adjusting for known prognostic 
determinants (Daling et al., 2002). Multiple 
hypotheses have been formulated to 
explain this apparent paradox. Women in 
this age group are not routinely screened 
by mammography; thus, there could be a 
delay in diagnosis leading to the detec-
tion of tumors at a more advanced stage. 
Decreased immune surveillance due to a 
transient immunosuppressive state, rela-
tive insulin resistance, and associated 
high circulating insulin levels, and altered 
melatonin levels induced by pregnancy 
and childbirth, have also been suggested 
as factors contributing to the worse out-
come of tumors diagnosed shortly after 
pregnancy. Pregnancy-associated hor-
mones, particularly prolactin, have been 
implicated as promoters of tumor cell 
growth and progression. Supporting this 
idea, a large fraction of breast tumors 
express prolactin and its receptor; thus, 
in addition to its systemic effects, prolactin 
may also act as a local autocrine/para-
crine factor.
Almost all epidemiological and 
molecular studies have focused on fac-
tors affecting breast epithelial cells, while 
the potential contribution of the microen-
vironment and extracellular matrix (ECM) 
composition to breast cancer risk and 
disease progression has not been thor-
oughly investigated. Many lines of evi-
dence suggest that these components 
may play important roles in breast cancer. 
High mammographic breast density is a 
significant risk factor for breast cancer, but 
the molecular mechanism underlying this 
observation is unknown. Polymorphism 
in CXCL12 (SDF-1), a chemokine that is 
overexpressed in breast tumor stroma and 
promotes tumor cell invasion and metas-
tasis, has recently been demonstrated 
to be associated with increased breast 
cancer risk. Data obtained in numer-
ous model systems and human cancer 
types describing alterations in stromal 
cells and ECM composition during tumor 
progression suggest that changes in the 
microenvironment and tissue architec-
ture contribute to tumorigenesis (Bissell 
et al., 2003). Correlating with this, a gene 
expression signature reflecting activated 
stroma that is characteristic of tumors and 
wound healing is associated with shorter 
overall and disease-free survival. Despite 
all this evidence indicating that pathologic 
changes in the microenvironment influ-152 ence tumor progression and clinical out-
come, the role of physiologic alterations in 
breast tissue architecture in breast tumori-
genesis has not been analyzed.
The mammary gland is a unique 
organ in that it undergoes dramatic tis-
sue remodeling depending on endocrine 
status. Monthly fluctuations in hormone 
levels, pregnancy, lactation, and involu-
tion all induce dramatic changes in the 
composition of the breast microenviron-
ment and ECM, similar to that observed 
during wound healing and inflammation. 
All these alterations could influence tum-
origenesis and could potentially explain 
the worse outcome of breast tumors diag-
nosed shortly after pregnancy (Figure 1). 
Testing these hypotheses was the goal 
of a study by McDaniel et al. published 
in a recent issue of American Journal of 
Pathology (McDaniel et al., 2006).
McDaniel and colleagues used a 
three-dimensional in vitro culture assay 
and a xenograft model of breast can-
cer to investigate the role of physiologic 
changes in ECM composition on mam-
mary epithelial and tumor cell behavior. 
First, they determined that ECM isolated 
from involuting rat mammary glands has 
increased fibrillar collagen, fragmented 
laminin, and fibronectin content and 
elevated MMP (matrix metallo-protease) 
activity compared to ECM purified from 
nulliparous glands. Next, they analyzed 
the growth of MCF-12A immortalized 
human mammary epithelial cells on matrix 
pads containing nulliparous or involuting 
matrix, or Matrigel (ECM produced by 
tumor cells). Cells grown on nulliparous 
matrix formed duct-like structures, while 
those plated on involuting matrix and 
Matrigel grew as spheroids, suggesting 
that only nulliparous matrix contains fac-
tors necessary for branching behavior. In 
contrast to the nontumorigenic MCF-12A 
cells, a highly tumorigenic variant of the 
MDA-MB-231 breast cancer cell line only 
grew as disorganized organoids invading 
the surrounding stroma in all three matri-
ces tested. Analysis of the migratory and 
invasive behavior of both cell lines in tran-
swell insert assays revealed that nontu-
morigenic MCF-12A cells were immotile 
and noninvasive with all matrices, while 
the invasion but not the migration of MDA-
MB-231 cells was influenced by the matrix 
with the highest response observed to 
involuting matrix. To investigate if involut-
ing matrix also promoted tumor invasion 
and metastasis in vivo, McDaniel and 
coworkers mixed MDA-MB-231 cells with various matrices, injected them orthotopi-
cally into the mammary fat pad of immu-
nodeficient mice, and analyzed tumor 
growth and metastatic behavior. While 
primary tumor growth was not affect-
ed by the origin of the admixed matrix, 
metastasis to the lung, liver, and kidney 
was significantly promoted by involuting 
matrix. To begin dissecting the mecha-
nisms by which the involuting matrix may 
exert this effect, McDaniel et al. observed 
increased angiogenesis and VEGF levels 
in primary tumors originating from cells 
mixed with involuting matrix. Additionally, 
these tumors contained higher numbers 
of smooth muscle actin-positive mouse 
myofibroblasts, cells characteristic of 
reactive stroma.
The study by McDaniel et al. high-
lights the importance of ECM in breast 
tumorigenesis and warrants further stud-
ies in this area. Specifically, the relevance 
of the results for human disease has to 
be evaluated, and the molecular proc-
esses underlying the observed effects 
have to be deciphered in order to move 
these findings closer to clinical relevance 
and application. Interestingly, prior studies 
from the same lab have demonstrated that 
the protumorigenic effects of the involut-
ing ECM may be breast cancer subtype 
dependent, since it was only observed 
with the ER-negative MDA-MB-435 and 
MDA-MB-231 breast cancer cells, but 
not with the ER-positive cell line MCF-7, 
nor with a nonmetastatic variant of the 
MDA-MB-435 cells (Bemis and Schedin, 
2000). Thus, once again it appears that 
tumorigenesis is the result of a symbiotic 
relationship between transformed tumor 
epithelial cells and their microenviron-
ment. Changes in both tumor and stro-
mal cells are necessary for breast tumor 
progression, therefore therapeutically tar-
geting both at the same time may be the 
optimal approach to harness and poten-
tially conquer this cancer.
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Rationale for combining inhibitors in 
the mTOR pathway
Rapamycin, a macrocylic antibiotic in com-
plex with a 12 kDa immunophillin (FKBP12) 
potently inhibits mTORC1 signaling, result-
ing in cytostatic or cytotoxic effects on can-
cer cells. Consistent with the “oncogene 
addiction” hypothesis, several studies have 
indicated that cells lacking PTEN function, 
and hence constitutive Akt activation, are 
hypersensitive to rapamycin (reviewed 
in Hay, 2005). However, there are clear 
exceptions, and reexpression of PTEN 
does not necessarily induce resistance to 
rapamycin. Other factors clearly modulate 
sensitivity to rapamycins. IGF-I and, less 
potently, insulin are unique among growth 
factors tested in their ability to overcome 
the inhibitory effects of rapamycin on pro-
liferation and apoptosis (Hosoi et al., 1999). 
However, for most cancer cells under nor-
mal growth conditions with exogenous 
growth factors, the effect of rapamycin and 
its analogs is largely cytostatic, leading to 
decreased transit through G1 phase and 
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